Patients with early-stage lung cancer had lower plasma CXCL14 levels than patients with lung cancer at later stages (stage I: 1452.40 pg/ml, stage II: 1898.00 pg/ml, stage III: 2231.00 pg/ml, stage IV: 2661.62 pg/ml, P=0.041). This evidence concerns the gene CXCL14 and lung cancer.